Key Highlights

● DIAMOND-1 and DIAMOND-2 missed their primary endpoint on May 29, 2026.

● Oculis does not currently plan an FDA filing for OCS-01 in diabetic macular edema.

● Privosegtor holds FDA Breakthrough Therapy and EMA PRIME designations.

● Cash and short-term investments were $277.6 million at March 31, 2026.

When a late-stage trial misses its primary goal, a drug developer's regulatory roadmap can change quickly. Oculis Holding AG (NASDAQ:OCS) experienced that on May 29, 2026, when its DIAMOND Phase 3 trials of OCS-01 eye drops in diabetic macular edema failed to meet their primary endpoint. The company said it does not currently plan to file with the US Food and Drug Administration for that indication and is redirecting resources. The regulatory spotlight has shifted to other programs, and investors may focus on those milestones. No major US index membership has been verified.

Latest Company Context

According to the topline announcement, neither DIAMOND-1 nor DIAMOND-2 met the primary endpoint, a mean change in best corrected visual acuity from baseline to Week 52, and the key secondary endpoint was also missed. Retinal thickness fell substantially versus vehicle, and the drug was well tolerated with no unexpected adverse events. More than 800 patients were enrolled at 119 sites. Chief executive Riad Sherif said the company was "naturally disappointed" that the retinal thickness reduction did not translate into visual acuity gains. Oculis said the results are preliminary and still under review. Before the readout, the company had said it would plan an NDA submission in the fourth quarter of 2026 if results were positive.

Key Business and Index Drivers

Regulatory attention now centres on privosegtor, in optic neuritis and related optic neuropathies. In its first-quarter 2026 update, Oculis said the FDA granted Breakthrough Therapy designation and the European Medicines Agency granted PRIME designation. The FDA also agreed a Special Protocol Assessment covering the design, size, analysis and endpoints of the registrational PIONEER-1 trial, which the company says sets a clear path to an NDA, subject to trial success. PIONEER-2 is planned to mirror it.

A second program, licaminlimab for dry eye disease, has the PREDICT-1 trial recruiting, with topline results expected around the end of 2026. Oculis reported $277.6 million in cash and short-term investments at March 31, 2026, with runway guided into the second half of 2029. No index linkage has been verified, so company-specific milestones may matter most. Oculis also lists on the Nasdaq under the symbol OCS and on a Swiss venue under XICE, per its own releases, though listing details do not imply index inclusion.

What Investors Should Watch

Investors may watch the full DIAMOND data presentation and any discussion with regulators about whether a narrower path for OCS-01 exists, though the company has not signalled one. Progress in activating PIONEER-1 sites and starting enrollment may indicate how quickly privosegtor advances. The PREDICT-1 readout around year-end could be the next major binary event. Cost discipline is also relevant: first-quarter net loss was $36.8 million, and the stated runway assumes management keeps spending within plan. Any further capital raising, including at-the-market issuance that supported recent cash growth, may be monitored, as might upcoming quarterly updates and conference presentations. The company also has other earlier-stage assets, including OCS-05 in acute optic neuropathy, which has received orphan drug designation from both the FDA and the EMA, according to earlier company disclosures.

A Narrower Path, a Longer Runway

Oculis enters the final quarter of 2026 with a changed regulatory outlook: a diabetic macular edema filing is off the table for now, while designations and a Special Protocol Assessment support the privosegtor program. Strong cash reserves may give the company time, but clinical outcomes still determine the path. Investors may also compare how quickly the company can convert designations into pivotal results, since regulatory flexibility does not remove clinical risk.